| HHS Artificial Intelligence Task Force (AI TF): Research and Discovery Working Group (R&D WG) |
Committee, Work group, Advisory group, or Task Force |
ACF, AHRQ, CDC, FDA, HRSA, OCR, OGC, SAMHSA |
NIAID, NLM |
In response to the President’s EO on Safe, Secure, and Trustworthy Development and Use of AI, HHS is developing an AI Strategy, including a portion that will focus on Research & Discovery. Section 5 of the EO outlines efforts related to support responsible AI development and use. This Working Group has been established to coordinate actions in support of this EO. |
| HHS Artificial Intelligence Task Force: Ethical and Responsible Use WG |
Committee, Work group, Advisory group, or Task Force |
ASPE, AHRQ, CDC, CMS, FDA, ONC |
OD/OSP |
Working group to examine the ethical and responsible use of AI in the context of health care delivery, public health, and drug and device development. Key policy concerns included ethics and scientific integrity, accountability and responsibility, disclosure and transparency, privacy, fairness and equity, and safety and reliability. Input from WG informed the HHS Strategic Plan on AI. |
| HHS Behavioral Health Coordinating Council (BHCC) |
Committee, Work group, Advisory group, or Task Force |
ACF, AHRQ, ASPE, CDC, CMS, FDA, OASH, OS, SAMHSA |
NIDA, OD/IMOD |
The BHCC is tasked with coordinating all federal government resources to address inequities and gaps within the mental health and substance use disorder system. |
| HHS Behavioral Health Coordinating Council (BHCC), Behavioral Health Integration Subcommittee |
Committee, Work group, Advisory group, or Task Force |
ACL, AHRQ, CDC, CMS, HRSA, IHS, SAMHSA |
NIAAA, NIDA, NIMH |
The Behavioral Health/Primary Care Integration Subcommittee addresses the need to improve the integration of mental health and primary care services. This group convenes bi-monthly to share agency initiatives in this area and collaborate on new initiatives to promote this integration. |
| HHS Behavioral Health Coordinating Council (BHCC), Buprenorphine Availability Subcommittee |
Committee, Work group, Advisory group, or Task Force |
ACF, AHRQ, ASPE, CDC, CMS, FDA, OASH, OS, SAMHSA |
NIAAA, NIDA, NIMH |
The BHCC is tasked with coordinating all federal government resources to address inequities and gaps within the mental health and substance use disorder system. |
| HHS Behavioral Health Coordinating Council (BHCC), Children and Youth Behavioral Health Subcommittee |
Committee, Work group, Advisory group, or Task Force |
CMS, FDA, HRSA, OASH, SAMHSA |
NICHD, NIDA, NIMH |
The BHCC is tasked with coordinating all federal government resources to address inequities and gaps within the mental health and substance use disorder system. |
| HHS Behavioral Health Coordinating Council (BHCC), Children and Youth Subcommittee |
Committee, Work group, Advisory group, or Task Force |
ACF, ACL, AHRQ, ASPE, CDC, CMS, FDA, HRSA, IHS, OASH, OSG, SAMHSA |
NICHD, NIDA, NIMH, NIMHD |
Subcommittee of HHS Behavioral Health Coordinating Council (BHCC), addressing these high level priorities: • Ensure children, youth, and caregivers have access to appropriate behavioral health prevention resources, screening, referral, and treatments in their communities, schools, and early education settings.• Address behavioral health needs resulting from the COVID-19 pandemic. • Advance health equity by addressing the health needs of underserved communities. • Support the behavioral health workforce that serves children and youth. |
| HHS Behavioral Health Coordinating Council (BHCC), Contingency Management Subcommittee |
Committee, Work group, Advisory group, or Task Force |
ACF, AHRQ, ASPE, CDC, CMS, FDA, OASH, OS, SAMHSA |
NIAAA, NIDA, NIMH |
The BHCC is tasked with coordinating all federal government resources to address inequities and gaps within the mental health and substance use disorder system. |
| HHS Behavioral Health Coordinating Council (BHCC), Expanding Access to Naloxone Subcommittee |
Committee, Work group, Advisory group, or Task Force |
ACF, AHRQ, ASPE, CDC, CMS, FDA, OASH, OS, SAMHSA |
NIAAA, NIDA, NIMH |
The National Institutes of Health (National Institute on Drug Abuse; NIDA) Serves as Co-Chair with the Food and Drug Administration (FDA) on this inter-agency subcommittee addressing drug overdose. NIDA participates on its constituent working groups whose topics include: drafting and implementation of the HHS Overdose Prevention Strategy; expanding access to contingency management; addressing pharmacy availability of buprenorphine; expanding access to naloxone; and determining the public health impact of kratom scheduling; and improving clinician education on controlled substance prescribing. |
| HHS Behavioral Health Coordinating Council (BHCC), High Dose Buprenorphine Subcommittee |
Committee, Work group, Advisory group, or Task Force |
FDA |
NIDA |
The National Institutes of Health (National Institute on Drug Abuse; NIDA) Serves as Co-Chair with the Food and Drug Administration (FDA) on this inter-agency subcommittee addressing drug overdose. NIDA participates on its constituent working groups whose topics include: drafting and implementation of the HHS Overdose Prevention Strategy; expanding access to contingency management; addressing pharmacy availability of buprenorphine; expanding access to naloxone; assessing the landscape of prescription stimulant use and misuse; and improving clinician education on controlled substance prescribing. |